{
    "pmcid": "11009965",
    "qa_pairs": {
        "How does AlphaFold-Multimer contribute to the design of SARS-CoV-2 nanobody binders?": [
            "By predicting the structure of nanobody\u2013antigen complexes",
            "By identifying mutations in the SARS-CoV-2 spike protein",
            "By simulating the immune response to SARS-CoV-2",
            "By designing small molecule inhibitors for the spike protein"
        ],
        "In what way can AlphaFold-Multimer be used in virtual screening for SARS-CoV-2 nanobody candidates?": [
            "By predicting binding modes with the spike protein",
            "By generating random nanobody sequences",
            "By identifying viral genome sequences",
            "By screening for potential vaccine candidates"
        ],
        "What future direction is suggested for improving AlphaFold-Multimer's utility in drug discovery?": [
            "Integration with other computational tools",
            "Development of a mobile application for predictions",
            "Focus on predicting carbohydrate interactions",
            "Expansion to include bacterial protein interactions"
        ],
        "What is a key limitation of AlphaFold-Multimer mentioned in the context of SARS-CoV-2 nanobody design?": [
            "Challenges in predicting antibody\u2013antigen complexes accurately",
            "Inability to model protein folding in real-time",
            "Lack of integration with experimental data",
            "Limited to predicting homomeric interfaces only"
        ],
        "What is the primary advantage of AlphaFold-Multimer over AlphaFold2 in predicting protein interactions?": [
            "Improved accuracy in predicting heteromeric interfaces",
            "Faster computational speed for predicting protein structures",
            "Ability to predict protein-DNA interactions",
            "Enhanced visualization of protein folding pathways"
        ]
    }
}